



ASX Release

December 2015 Appendix 4C

Melbourne, Australia, 25 January 2016

Prescient Therapeutics Limited (“**Prescient**” or “**the Company**”) provides the following Appendix 4C in relation to the quarter ended 31 December 2015.

In January 2016, the Company carried out investor roadshows in the US meeting key institutions and investment advisors and also presented at Biotech Showcase 2016 in San Francisco and NobleCon12 in Florida.

Cash at 31 December 2015

Cash at the end of the quarter, as detailed in the attached Appendix 4C, was approximately \$1.93 million.

Subsequent to the end of the quarter the Company has now received its 2014/2015 Research and Development Incentive Grant and Overseas Finding Grant amounting to \$463,538.

Key activities during the quarter

During the quarter, the Company announced a Share Purchase Plan (SPP) fully which was underwritten up to a target amount of \$1.03 million to underpin next stage development of its lead oncology costs. The SPP closed oversubscribed with \$1.2 million worth of subscriptions received. All applications under the SPP were scaled back on an equal basis and a total of 17,174,368 fully paid ordinary shares were issued at \$0.054 (5.4 cents) per share, being a 20% discount to the 5 day volume weighted average price (VWAP) before 23 November 2015. The final SPP results raised a total of \$927,416 (before costs).

Funds raised from this SPP will enable the Company to:

- Initiate and complete a Phase I Acute Myeloid Leukemia trial at the Moffitt Cancer Center in Florida
- Commence recruitment for a Phase II breast cancer trial at the Montefiore Medical Center in New York (part of the Albert Einstein College of Medicine)
- Continue patient recruitment to a key Phase I ovarian cancer trial already underway at the Moffitt Cancer Center.

Also during the quarter, Prescient announced that following the oversubscribed SPP, that it has subsequently raised approximately \$1.0 million through a Top Up Placement. A total of 19,319,076 fully paid ordinary shares were issued at \$0.054 (5.4 cents) per share, raising \$1,043,230 (before costs).

The Company announced the appointment of an internationally regarded leukaemia authority to its Scientific Advisory Board, Professor Farhad Ravandi MD who is based at the MD Anderson and Moffitt Cancer Center, which is one of the world’s most prestigious cancer institutions.



He currently holds position as Professor and Chief, Section of Developmental Therapeutics within the Department of Leukemia, Division of Cancer Medicine at the Texas facility. His PTX appointment is especially significant ahead of the Company's upcoming clinical trial in Acute Myeloid Leukaemia (AML) in early 2016.

The Company also announced that it has appointed H. Lee Moffitt Cancer Center's Professor Jeffrey Lancet MD to PTX's Scientific Advisory Board ("SAB"). Professor Lancet is a medical oncologist whose work involves the development and implementation of clinical trials using small molecule inhibitors in acute leukaemias.

During the quarter, Prescient announced that Dr Robert Crombie resigned from his position as Managing Director. The Company initiated a search for his replacement, with Mr Paul Hopper leading the Company in his ongoing executive director role until a replacement is appointed. Dr Crombie intends to focus on other business opportunities.

About Prescient Therapeutics Limited (PTX)

PTX is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. This highly promising compound is now the focus of three current clinical trials. The first is a Phase Ib/II study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York. A Phase Ib/II trial of the compound in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at Florida's H. Lee Moffitt Cancer Center. These trials are funded in part by grants from the U.S. National Cancer Institute. In addition, PTX has recently received IND allowance for a Phase Ib/II trial evaluating PTX-200 as a new therapy for Acute Myeloid Leukemia.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.

Further Inquiries:

Steven Engle

Chairman

+1 858 922 7768 (US)

Paul Hopper

Executive Director

+61 406 671 515

Rudi Michelson

Monsoon Communications

+61 3 9620 3333



Prescient Therapeutics Limited
Level 4, 100 Albert Road, South Melbourne, VIC 3205
Phone: +61 3 9692 7222 Fax: +61 3 9077 9233
ABN: 56 006 569 106 ACN: 006 569 106
www.prescienttherapeutics.com

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005, 17/12/2010

Name of entity

Prescient Therapeutics Limited

ABN

56 006 569 106

Quarter ended ("current quarter")

31 December 2015

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (6 months) \$A'000
1.1 Receipts from customers	-	-
1.2 Payments for:		
(a) staff costs	(192)	(285)
(b) advertising and marketing	(19)	(25)
(c) research and development	(107)	(292)
(d) leased assets	-	-
(e) other working capital	(351)	(534)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	3	3
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Other items		
(a) Net GST (paid to)/recovered from ATO	-	113
(b) R & D tax rebate received	95	95
(c) Government grant received	-	-
(d) R&D contract contributions received	-	-
Net operating cash flows	(571)	(925)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (6 months) \$A'000
1.8 Net operating cash flows (carried forward)	(571)	(925)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other (provide details if material)	-	-
Net investing cash flows	-	-
1.14 Total operating and investing cash flows	(571)	(925)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	1,971	1,971
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	-
1.20 Capital raising costs	(202)	(202)
Net financing cash flows	1,769	1,769
Net increase (decrease) in cash held	1,198	844
1.21 Cash at beginning of quarter/year to date	755	1,043
Exchange rate adjustments to item 1.20	(23)	43
1.23 Cash at end of quarter	1,930	1,930

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	192
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Directors' fees and Executive Directors' salaries paid during the December 2015 quarter.
--

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

-

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

-

Financing facilities available

Add notes as necessary for an understanding of the position.

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	1,910	735
4.2	Deposits at call	20	20
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)		1,930	755


Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	-
5.2	Place of incorporation or registration	-
5.3	Consideration for acquisition or disposal	-
5.4	Total net assets	-
5.5	Nature of business	-

+ See chapter 19 for defined terms.

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:  _____ Date: 25 January 2016
(Company Secretary)

Print name: Melanie Leydin

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirement requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.